Shares of Kala Pharmaceuticals KALA fell 0.5% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share increased 9.26% over the past year to ($0.49), which beat the estimate of ($0.68).
Revenue of $3,266,000 higher by 204.95% from the same period last year, which missed the estimate of $4,180,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 05, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/yu62x3fd
Recent Stock Performance
Company's 52-week high was at $14.68
52-week low: $6.00
Price action over last quarter: down 13.36%
Company Description
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. The company's two marketed products are EYSUVIS and INVELTYS.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.